Imunon, Inc. Debt Instrument, Unamortized Discount (Premium), Net
Imunon, Inc. (IMNN) had Debt Instrument, Unamortized Discount (Premium), Net of $196.32 thousand as of 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2020-03-25
- 2019-12-31: Debt Instrument, Unamortized Discount (Premium), Net $196.32K.
- 2019-09-30: Debt Instrument, Unamortized Discount (Premium), Net $293.78K.
- 2019-06-30: Debt Instrument, Unamortized Discount (Premium), Net $391.24K.
- 2019-03-31: Debt Instrument, Unamortized Discount (Premium), Net $485.50K.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2019-12-31 | $196.32K 10-K · filed 2020-03-25 |
| 2019-09-30 | $293.78K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $391.24K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $485.50K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $582.96K 10-K · filed 2019-03-29 |
| 2018-09-30 | $680.42K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $777.88K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |